Protecting 3 Generations of Your Family With Your Baby’s Cord Blood

At Cordlife, we understand that as a parent, you did not have a chance to store your own precious cord blood. That is why, we have extended the biological insurance coverage of storing your baby’s cord blood to 3 generations of your family with CordBlood Network.

Unlike other cord blood banks that provide basic cord blood banking for only your child, CordBlood Network, a Cordlife initiated programme will assist in the search for a matching cord blood unit should the need arise for your child, his/her biological parents and biological grandparents. With CordBlood Network, you can now protect 3 generations of your family by storing your baby’s cord blood with Cordlife.

Facts about Cord Blood Banking

Chances of using stem cells

  • 1 in 217 chance that a person may need cord blood stem cells for treatment in their life time1.
  • 12 cord blood units were releases for transplants and therapeutic applications by Cordlife Group.
  • 73% of cord blood transplants by ViaCord were self-use, 27% were from siblings1.

Higher chance of finding a match within the patient’s family

  • The odds of finding a match in the same racial group is around 1 in 20.0002.
  • The procurement fee for donated cord blood in Singapore is between $30,000 and $75.0002
  • 25% chance of a 100% match between siblings. A perfect match is required for bone marrow transplants, but not in cord blood transplant3.
Source
1. Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U. S. Biol Blood Marrow Transplant. 2008;14:316-322.
2. Joan Chew (July 18, 2013). Criterion for new stem-cell transplant. The Straits Time
3. National Marrow Donor Program Webiste. www.marrow.org. Accessed April 10, 2014.

Related items

  • Advantages of Cordlife's Processing and Storage Methods Advantages of Cordlife's Processing and Storage Methods

    celloptima logoHarvesting MSCs and EpSCs from Cord Lining with CellOptima™

    Patented Technology with 16 Patent Protection granted and 10 more pending

    Available exclusively at Cordlife in India, CellOptima™ can isolate and expand two types of stem cells; MSCs and EpSCs, from your baby’s cord lining.

    More than 20 years ago, bone marrow was found to contain MSCs. Subsequently, scientists also found that Wharton’s Jelly from the umbilical cord contain MSCs as well. More recently, a team of award-winning doctor and scientist from Singapore made significant inroad in the world with the discovery of two powerful stem cell types, MSCs and EpSCs, from cord lining. Together, the Cambridge and Stanford University trained duo developed a unique technology known as CellOptima™, designed to harvest and multiply stem cells from cord lining. This revolutionary discovery subsequently led the team to receiving patent grants from 16 countries including United States, China, Singapore, Hong Kong and patent grants from another 10 countries are still pending for final approval. These patents prohibit anybody other than the patent owner from harvesting stem cells from cord lining.
    tip Quick Tip
    What makes CellOptima™ special?
    CellOptima™ is an original invention from Singapore. Patent protection of CellOptima™ has been granted by many countries because the technology is novel, first-of-its-kind and useful. All patents granted for CellOptima™ prevents other companies from harvesting stem cells from cord lining.

    List of Clinical Trials with Stem Cells harvested with CellOptima™

    Focus  Partner Universities or Research Institutions 
    Heart restoration and repair
    • National University of Singapore
    • Hamburg University, Heart Centre, Germany
    Wound management and burns 
    • Shriner’s Children’s Burns Hospital, United States
    • Chinese University of Hong Kong
    • National Burns Centre, Hanoi, Vietnam
    Cornea regeneration 
    • Singapore Eye Research Institute, Singapore
    • National Eye Institute, Hanoi, Vietnam
    Liver regeneration
    National University of Singapore
    Skin & hair rejuvenation
    • Camden Medical Centre, Singapore
    • BK Clinic, South Korea
    • National Institute of Dermatology, Hanoi, Vietnam 
    Insulin-producing cells
    • National Cancer Centre, Singapore
    • National University of Singapore
    Neuronal differentiation for hearing impairment Stanford University, United States
    Bone differentiation, repair and regeneration
    • AO Foundation, Switzerland
    • Keele University, United Kingdom
    Hemophilia A National Cancer Centre, Singapore
    Human feeder layer for stem cell culture Duke University, United States and National University of Singapore (co-collaboration)
  • Potential Applications of Umbilical Cord Lining Stem Cells Potential Applications of Umbilical Cord Lining Stem Cells

    Potential Therapeutic Application

    SourceUmbilical cord lining
    Types of stem cells Mesenchymal stem cells (MSCs) Epithelial stem cells (EpSCs)

    Potential Treatment for

    Tissue repair

    • Myocardial infarction (heart muscle repair)
    • Osteoarthiritis
      (cartilage repair and other orthopedic applications)
    • Stroke
    • Pulmonary fibrosis

    HSCs engraftment support

    • Shorten time of engraftment
    • Reduce immune system complications

    Immune modulation

    • Type 1 diabetes
    • Crohn's disease
    • Graft versus host disease (GvHD)

    Wounds/soft tissue repair

    • Surface ulcers
      (e.g. diabetic ulcers)
    • Various types of burns
    • Tissue trauma
    • Lining of liver
    • Replacement of corneal membrane

    Today, more than 190 clinical trials1 are on-going worldwide to uncover the potential of MSCs. Thus far, encouraging results have been published; stem cell treatments have been proven safe and capable of repairing damage caused by stroke and heart disease. MSCs have also been used in combination with HSCs as a dual therapy to promote faster engraftment of HSCs and to reduce immune system complications2.

    Although there is evidence that MSCs can be changed to certain types of Epithelial cells, the cells cannot be changed into Epithelial stem cells (EpSCs). The difference between Epithelial stem cells and Epithelial cells is that Epithelial stem cells can differentiate into all different epithelial cell types such as skin, cornea, lining of the gut, etc. on demand. Whereas, (non-stem) Epithelial cells have already reached terminal differentiation so the cells cannot be further changed into different Epithelial cell types when needed. Thus, MSCs and EpSCs cannot be replaced by each other.

    1 ClinicalTrials.gov. Accessed on 4 January 2012. (http://www.clinicaltrials.gov/ct2/results?term=mesenchymal+stem+cells)
    2 Battiwalla M, Hematti P. 2010. Cytotherapy. 1 January 2010.

    Worldwide researches on diseases treated with MSCs by various Universities or Research Institutions:

    DiseasesName of universities or research Institions
    Stroke University Hospital, Grenobe, France
    Spinal Cord Injury
    • Cairo University, Egypt
    • Chinese University of Hong Kong
    Multiple Sclerosis
    • Spain-Carlos Health Institute
    • University of Cambridge, U.K.
    • Cleveland Clinic, U.S.
    Amylotrophic Lateral Sclerosis Hadassah Medical Organization, Israel
    Parkinson's Disease Jaslok Hospital and Research Centre, India
    Multiple System Atrophy Yonsei University, South Korea
    Liver Disease Cytori Therapeutics, U.S.
    Diabetic Foot Ulcer
    • Third Military Medical University, China
    • Washington DC Veterans Medical Centre, U.S.
    • Ruhr-University Bochum, Germany
    Diabetes
    • FuZhou General Hospital, China
    • Uppsala University, Sweden
  • How Are Stem Cells Used How Are Stem Cells Used

    Stem Cell Transplantation

    This is done to reconstitute a patient's blood and immune system, following treatments such as chemotherapy or radiotherapy, which destroys blood cells.

    The stem cells are infused directly into the patient's bloodstream, which migrate to the bone marrow. Inside the bone marrow environment, the stem cells begin differentiating into the three blood cell types - red blood, white blood and platelets. This initiates the regeneration of the patient's blood and immune system.

    The first cord blood transplant was performed in 1988 in France, which successfully treated a 5-year old boy with Fanconi's Anaemia. To date there have been more than 30,000 cord blood stem cell transplants reported worldwide.1

    Cellular Therapies

    Many newer applications are still undergoing development. In some cases, like spinal cord injury and heart attacks, the cells are directly injected into the damaged tissues. Some of the benefits experienced appear to be due to new blood vessel formation, which restores blood flow to damaged tissue.

    As these treatments develop, we expect to see cord blood stem cells used in different ways. In some cases, the stem cells will be treated in the laboratory to make new cell types before use. In other cases, they will be delivered directly into the damaged tissue.

    View video on "Cordlife's successful transplant to treat leukemia".

    Source:
    Ballen K., Gluckman E., Broxmeyer H. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122(4):491-498.
  • Cordlife’s Success Stories Cordlife’s Success Stories

    Cordlife is proud to help these families in using their cord blood units stored in various Cordlife facilities for successful stem cell transplantations.

    Ray Fu

    Little Ray Fu was suffering from leukaemia at a tender age of three. Despite a nation-wide search for bone marrow stem cells, a suitable donor could not be found. Fortunately, baby sister of Ray Fu, Rachel Fu was born during that critical period which enabled the family to store Rachel Fu's cord blood with CordLife, for Ryan Fu's transplant. Now 10, Ray Fu is in school and his leukaemia is in remission.

    "We were elated when Rachel Fu's blood was shown to be a 100-per-match for Ray Fu. The healthy cell from his sister re-populated in his bone marrow and revived his immune system," said Dr Tan Ah Moy, Head and Senior Consultant for Haematology and Oncology Services at the KK Women's and Children's Hospital where the transplant was performed.

    Source: The Straits Times, 1 July 2004
    Justin

    Justin (alias) was diagnosed with a common childhood cancer, neuroblastoma, at a tender age of one and half years old. Over the course of 1 year, the child had to endure numerous rounds of high-dose chemotherapy to treat his condition. Chemotherapy destroyed cancer cells, but at the same time also killed normal cells. Fortunately, Justin’s parents had his cord blood stored at birth with CordLife. The cord blood stem cells were infused back to his body after a course of chemotherapy in January 2011 at Queen Mary Hospital and he was discharged from hospital after 3 months. The cord blood unit used had been cryopreserved in our Hong Kong facility for 29 months. CordLife is very proud to achieve this milestone in the cord blood banking industry in Hong Kong.

    Georgia

    An accident at birth 2.5 years ago deprived Baby Georgia of oxygen to her brain, resulted in cerebral palsy. The damage to the toddler's brain caused her to move involuntarily, suffer from muscle spasms and have up to 50 seizures a day. It was only after CordLife put the family in touch with a renowned neurosurgeon that enable Georgia to be infused with her own cord blood, also stored by CordLife. Her conditions have improved since then.

    "Georgia has made good progress since her stem cell infusion. She has better visual focus and eye contact with adults during play. She has more vocalization and tries to 'sing-a-song' by making different sounds to nursery rhymes. Georgia has improved postural and head control and is observed to be reaching more with her arms," said Ms. Jaclyn Tan, Consultant Occupational Therapist at OzWorks Therapy.

    Source: The Sun, 3 December 2009
    Moinam

    Moinam was diagnosed Thalassamia when he was barely one year old. If left untreated, most of the children inflicted with this disorder do not live beyond the age of 10. Fortuitously, his newborn sister was free from Thalassamia and her cord blood stem cells were a perfect match for Moinam, with small amount of bone marrow to supplement the transplant, Moinam is now in his recovery phase and the results from his blood very heartening.

    "We decided to use a mixture of bone marrow and cord blood cells as it has a better and faster chance of success than only bone marrow cells. Bone marrow stem cells, on the other hand, could lead to Graft Versus Host Disease, triggered by the body's defense mechanism while the transfusion is being done. Not only increase the stem cell count, but also reduce the chance of any complications. It is the treatment of choice in such cases and leads to a complete cure," explained Dr Mukherjee, Medical Director of NetajiSubhash Chandra Bose Cancer Research Institute.

    Source: The Telegraph, 7 May 2011